



# Journal of Biological Sciences

ISSN 1727-3048

**science**  
alert

**ANSI***net*  
an open access publisher  
<http://ansinet.com>

## Global Emergence of Nosocomial Gram-negative Pathogens Possessing Carbapenem-hydrolyzing $\beta$ -lactamases

Simona Bratu and John Quale

Division of Infectious Diseases, State University of New York-Downstate Medical Center,  
Brooklyn, NY, USA

---

**Abstract:** Carbapenem antibiotics are typically reserved for serious nosocomial infections. Several classes of  $\beta$ -lactamases have emerged that possess carbapenem-hydrolyzing activity. Class A KPC-type  $\beta$ -lactamases have recently emerged in *Klebsiella pneumoniae* isolates from the northeastern United States. Class D OXA-type  $\beta$ -lactamases are typically found in *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates from southern Europe. Class B metallo- $\beta$ -lactamases are also typically found in *A. baumannii* and *P. aeruginosa*; regions in the Far East and Europe have been especially affected by bacteria carrying these enzymes. Most nosocomial pathogens that possess a carbapenem-hydrolyzing  $\beta$ -lactamases are frequently resistant to other classes of antibiotics, including aminoglycosides and fluoroquinolones. For infections caused by these highly resistant Gram-negative pathogens, polymyxin antibiotics are often administered, although concerns remain regarding their efficacy and toxicity.

**Key words:** Carbapenemase, antibiotics,  $\beta$ -lactamases

---

### INTRODUCTION

Antimicrobial resistance in hospital-acquired pathogens is associated with adverse clinical outcomes and increased healthcare expenditures. Carbapenem antibiotics are often reserved for the therapy of serious nosocomial infections due to Gram-negative bacilli. In particular, carbapenem antibiotics are often the agents of choice for therapy of infections due to *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Enterobacteriaceae* possessing extended-spectrum  $\beta$ -lactamases. Because these nosocomial pathogens are frequently resistant to other classes of antibiotics (including fluoroquinolones and aminoglycosides), effective therapeutic regimens are severely restricted when carbapenem resistance develops.

Although efflux systems, decreased cell wall permeability and altered penicillin-binding proteins can contribute to  $\beta$ -lactam resistance, in Gram-negative pathogens the primary defense is  $\beta$ -lactamase activity.  $\beta$ -lactamases have been categorized into four Ambler molecular classes. Classes A, C and D  $\beta$ -lactamases all possess serine at the critical site. Class B  $\beta$ -lactamases require the presence of zinc and are referred to as metallo- $\beta$ -lactamases. In this review,  $\beta$ -lactamases that contribute to carbapenem resistance are examined.

**Class A  $\beta$ -lactamases:** Several class A  $\beta$ -lactamases have been found to possess hydrolytic activity against carbapenems (Table 1). Sme-1 and Sme-2 have been recovered from carbapenem-resistant isolates of *Serratia marcescens* (Naas *et al.*, 1994; Queenan *et al.*, 2000). Sme-1 and Sme-2 were recovered from isolates in several cities in the United States and in London, but to date have remained distinctly unusual. Both enzymes were inhibited by clavulanic acid and tazobactam. The  $\beta$ -lactamase IMI-1 was recovered in two clinical isolates of *Enterobacter cloacae* from a hospital in California (Rasmussen *et al.*, 1996). The bacteria carrying Sme and IMI  $\beta$ -lactamases remained susceptible to third generation cephalosporins and their identification actually preceded the introduction of carbapenems into clinical practice. The NmcA  $\beta$ -lactamase has been recovered in isolates of *E. cloacae* (Nordmann, 1993; Naas and Nordman, 1994; Pottumarthy *et al.*, 2003). NmcA  $\beta$ -lactamase was chromosomally-encoded, closely related to IMI-1 and to Sme-1 and preferentially hydrolyzed imipenem. A fifth enzyme, GES-2, was found in an isolate of *Pseudomonas aeruginosa* from South Africa (Poirel *et al.*, 2001).

As noted, the finding of Sme, IMI, NmcA and GES-2  $\beta$ -lactamases has remained rare. In contrast, bacteria carrying KPC-type  $\beta$ -lactamases appear to be emerging. The first of these enzymes, KPC-1, was found

**Table 1: Susceptibility patterns bacteria possessing classes A  $\beta$ -lactamases with carbapenem-hydrolyzing activity**

$\beta$ -lactamase	Bacteria	No. of isolates (patients)	Country of origin	Imipenem MIC ( $\mu\text{g mL}^{-1}$ )	Concomitant* resistance	Concomitant susceptibility	References
Sme-1	<i>S. marcescens</i>	1	England	16		MEM,CAZ,FEP	Naas <i>et al.</i> (1994)
Sme1,2	<i>S. marcescens</i>	25	USA	256-512	MEM,ATM, FOX	CAZ	Queenan <i>et al.</i> (2000)
IMI-1	<i>E. cloacae</i>	2	USA	>32	TZB,FOX	CAZ,CTX,MEM	Rasmussen <i>et al.</i> (1996)
NmcA	<i>E. cloacae</i>	1	France	16	FOX	MEM,ATM,CTX	Naas <i>et al.</i> (1994)
NmcA	<i>E. cloacae</i>	1	USA	>32	MEM,FOX	TZB,CAZ,CTX,TMP -SMX,CIP,GM	Nordmann <i>et al.</i> (1993) Potlumarthy <i>et al.</i> (2003)
GES-2	<i>P. aeruginosa</i>	1	S. Africa	16	MEM,CAZ,TZB,ATM,GM,CIP	TOB	Poirle <i>et al.</i> (2001)
KPC-1	<i>K. pneumoniae</i>	1	U.S.A. (NC)	16	MEM,CAZ,TZB,ATM,GM		Yigit <i>et al.</i> (2001)
KPC-2	<i>S. enterica</i>	1	U.S.A. (MD)	16	MEM,CAZ,TZB,ATM	FEP	Miriagou <i>et al.</i> (2003)
KPC-2	<i>K. oxytoca</i>	1	U.S.A. (NY)	32	MEM,CAZ,TZB,ATM,TMP-SMX	GM	Yigit <i>et al.</i> (2003)
KPC-2	<i>E. cloacae</i>	4	U.S.A. (MA)	8	CAZ,FEP		Hossain <i>et al.</i> (2004)
KPC-2	<i>Enterobacter</i> spp.	3	U.S.A. (NY)	24->32	ERT		Bratu <i>et al.</i> (2005a)
KPC-2	<i>K. pneumoniae</i>	4	U.S.A. (MD)		ERT,ATM	FOX,CIP,FEP,AK,GM	Moland <i>et al.</i> (2003)
KPC-2	<i>K. pneumoniae</i>	19	U.S.A. (NY)	4 ->64	CAZ, TZB,AK,CIP		Bradford <i>et al.</i> (2004)
KPC-2	<i>K. pneumoniae</i>	29	U.S.A. (NY)	>32	CAZ, TZB,AK,CIP	PXB,TIG	Bratu <i>et al.</i> (2005b)
KPC-3	<i>E. coli</i>	7	U.S.A. (NJ)	3-16			Hong <i>et al.</i> (2005)
KPC-3	<i>K. pneumoniae</i>	24	U.S.A. (NY)	>4	CAZ,TZB,AK,GM	PXB,TET	Woodford <i>et al.</i> (2004)
KPC-2	<i>K. pneumoniae</i>	96	U.S.A. (NY)	8->32	MEM,ERT,CAZ	PXB,TIG,DOX,GM	Bratu <i>et al.</i> (2005e)

\* AK= amikacin; ATM = aztreonam; CAZ= ceftazidime; CIP= ciprofloxacin; CTX= cefotaxime; DOX=doxycycline; ERT= ertapenem; FEP= cefepime; FOX= cefoxitin; GM= gentamicin; MEM= meropenem; PXB= polymyxin B; TET=tetracycline; TIG= tigecycline; TMP-SMX= trimethoprim-sulfamethoxazole; TZB=piperacillin-tazobactam

in a carbapenem-resistant strain of *K. pneumoniae* (Yigit *et al.*, 2001). The finding of KPC-2, which differs from KPC-1 by a single amino acid change, has been reported in sporadic isolates of *Salmonella enterica* (Miriagou *et al.*, 2003), *K. oxytoca* (Yigit *et al.*, 2003) and *Enterobacter* spp. (Hossain *et al.*, 2004; Bratu *et al.*, 2005a). Isolates of *K. pneumoniae* with KPC-2 have also been identified (Moland *et al.*, 2003) and appear to be rapidly emerging in the New York City region, resulting in hospital outbreaks (Bradford *et al.*, 2004; Bratu *et al.*, 2005b). A third enzyme KPC-3, which has an additional amino acid substitution, has been found in *E. cloacae* (Bratu *et al.*, 2005a), *E. coli* (Hong *et al.*, 2005), and *K. pneumoniae* (Woodford *et al.*, 2004). A hospital outbreak, also in New York City, involved KPC-3 possessing *K. pneumoniae* (Woodford *et al.*, 2004). Unlike the chromosomal Sme, NmcA, and IMI-1  $\beta$ -lactamases, KPC enzymes have been found to reside on transmissible plasmids (Yigit *et al.*, 2001; Miriagou *et al.*, 2003), likely accounting for the variety genera carrying these enzymes. Most of the hospital outbreaks of *K. pneumoniae* have involved a small number of strains, however (Bradford *et al.*, 2004; Bratu *et al.*, 2005d; Woodford *et al.*, 2004). The *K. pneumoniae* possessing KPC enzymes isolates tend to be resistant to all  $\beta$ -lactam antibiotics and other classes of antibiotics, including aminoglycosides and fluoroquinolones. Therefore, therapy of infections due to these pathogens is extremely difficult. Occasional isolates retain susceptibility to gentamicin and amikacin. Most KPC-carrying *K. pneumoniae* are susceptible to the glycylicycline tigecycline and to polymyxin B, although resistance to the latter agent has been documented (Bratu *et al.*, 2005b).

**Class C:** Chromosomal AmpC  $\beta$ -lactamases can slowly hydrolyze imipenem. When expression of an AmpC enzyme is coupled with an additional mechanism of resistance, frank carbapenem resistance can result. The combination of porin loss and class C  $\beta$ -lactamase expression is an important cause of imipenem resistance in *P. aeruginosa* (Livermore, 1992; Pai *et al.*, 2001) and *Acinetobacter baumannii* (Quale *et al.*, 2003). Occasional isolates of *E. aerogenes* (Chow and Shlaes, 1991; Yigit *et al.*, 2002) and *K. pneumoniae* (Bradford *et al.*, 1997; Cao *et al.*, 2000; Martinez-Martinez *et al.*, 1999) can also develop resistance to imipenem secondary to the combination of porin loss and AmpC expression.

**Class D:** Several groups of class D oxacillin-hydrolyzing enzymes possess carbapenem-hydrolyzing activity (Table 2). OXA  $\beta$ -lactamases are typically inhibited by NaCl but variably inhibited by clavulanic acid. The first group, consisting of OXA-23 (Paton *et al.*, 1993; Donald *et al.*, 2000; Dalla-Costa *et al.*, 2003; Bonnet *et al.*, 2002) and OXA-27 (Afzal-Shah *et al.*, 2001), have 99% homology with one another. OXA23 (also known as ARI-1) is not inhibited by clavulamic acid and was first recovered in isolate of *A. baumannii* from Scotland (Paton *et al.*, 1993; Donald *et al.*, 2000). A strain of *A. baumannii* carrying OXA-23 has been found in hospitals in Brazil (Dalla-Costa *et al.*, 2003). OXA-23 has also been found in a strain of *Proteus mirabilis* from France, although this strain remained susceptible to imipenem (Bonnet *et al.*, 2002). One isolate of *A. baumannii* with OXA-27 from Singapore has been reported; this enzyme was only weakly inhibited by clavulamic acid (Afzal-Shah *et al.*, 2001). The second

Table 2: Susceptibility patterns of bacteria possessing class D β-lactamases with carbapenem-hydrolyzing activity

β-lactamase	Bacteria	No. of isolates (patients)	Country of origin	Imipenem MIC (μg mL <sup>-1</sup> )	Concomitant resistance*	Concomitant susceptibility	References
OXA-23	<i>A. baumannii</i>	1	Scotland	16	FOX,ATM	CAZ,GM, CIP	Paton <i>et al.</i> (1993) Donald <i>et al.</i> (2000)
OXA-23	<i>A. baumannii</i>	8	Brazil	>32	MEM,CAZ,TZB,SULB,AK,GM,CIP	PXB	Dalla-Costa <i>et al.</i> (2003)
OXA-23	<i>P. mirabilis</i>	10	France	0.25-0.5			Bonnet <i>et al.</i> (2002)
OXA-24	<i>A. baumannii</i>	29	Spain	128	MEM,CAZ,ATM,CIP	TOB	Bou <i>et al.</i> (2000b)
OXA-25	<i>A. baumannii</i>	1	Spain	64	MEM,CAZ,PIP,ATM,FEP		Afzal-Shah <i>et al.</i> (2001)
OXA-26	<i>A. baumannii</i>	1	Belgium	64	MEM,CAZ,PIP,ATM	FEP	Afzal-Shah <i>et al.</i> (2001)
OXA-27	<i>A. baumannii</i>	1	Singapore	16	MEM,CAZ,PIP,ATM		Afzal-Shah <i>et al.</i> (2001)
OXA-40	<i>A. baumannii</i>	1	France	256	MEM,CAZ,TZB,ATM,GM,CIP	AK,COL	Heritier <i>et al.</i> (2003)
OXA-40	<i>A. baumannii</i>	82	Spain	>16	TZB,CAZ,ATM,GM,AK,CIP		Lopez-Otsoa <i>et al.</i> (2002)
OXA-48	<i>K. pneumoniae</i>	1	Turkey	64	MEM,CAZ,TZB,FOX,FEP		Poirel <i>et al.</i> (2004)
OXA-58	<i>A. baumannii</i>	7	France	32	MEM,CAZ,FEP,TZB,ATM	COL	Heritier <i>et al.</i> (2005)

\*AK = amikacin; ATM = aztreonam; CAZ = ceftazidime; CIP = ciprofloxacin; COL = colistin; DOX = doxycycline; FEP = cefepime; GM = gentamicin; MEM = meropenem; PXB = polymyxin B; SULB = sulbactam; TOB = tobramycin; TZB = piperacillin-tazobactam

cluster of OXA enzymes possessing carbapenem-hydrolyzing activity include OXA-24 (Bou *et al.*, 2000b), -25, (Afzal-Shah *et al.*, 2001), -26 (Afzal-Shah *et al.*, 2001) and -40 (Heritier *et al.*, 2003). An outbreak of *A. baumannii* carrying OXA-24 has been reported in Spain; tobramycin was the only reported antibiotic displaying in vitro susceptibility (Bou *et al.*, 2000b). Single isolates of *A. baumannii* carrying OXA-25 (Afzal-Shah *et al.*, 2001), OXA-26 (Afzal-Shah *et al.*, 2001) and OXA-40 (Heritier *et al.*, 2003) have been documented; all were highly resistant to β-lactams. An outbreak of two major strains of *A. baumannii* possessing OXA-40 has also been documented in Spain (Lopez-Otsoa *et al.*, 2002). A third unrelated enzyme, OXA-48, has been recovered in a carbapenem-resistant strain of *K. pneumoniae* from Turkey (Poirel *et al.*, 2004). This isolate also carried multiple β-lactamases and had a porin defect, likely contributing to high-level β-lactam resistance. The fourth unrelated enzyme is OXA-58, recovered in carbapenem-resistant isolates of *A. baumannii* in France (Poirel *et al.*, 2005; Heritier *et al.*, 2005). Six patients from a burn unit were found to harbor the same strain of OXA-58 possessing *A. baumannii*. This enzyme was found residing on a plasmid and was detected in an unrelated environmental isolate of *A. baumannii*. (Heritier *et al.*, 2005). Several isolates of *A. baumannii* from Argentina possessing unidentified OXA-type enzymes have also been reported (Brown *et al.*, 1998; Afzal-Shah *et al.*, 1999). Many OXA β-lactamases are not easily transmissible and possess only weak carbapenemase activity (Paton *et al.*, 1993; Bonnet *et al.*, 2002; Afzal-Shah *et al.*, 2001; Bou *et al.*, 2000b; Poirel *et al.*, 2004). When OXA-24 was inserted into a susceptible *E. coli*, the MIC for imipenem rose from 0.12 to 1 μg mL<sup>-1</sup> (Bou *et al.*, 2000b). It appears that concomitant porin defects are necessary in order to reach a significant level carbapenem resistance in OXA-24 possessing *A. baumannii* (Bou *et al.*, 2000a).

**Class B:** Metallo-β-lactamases belong to the molecular class B of Ambler and are distinguished by the presence of zinc ion at their active site. They are inhibited by metal chelators such as ethylenediaminetetraacetic acid (EDTA) and thiol-based compounds and are not affected by the suicide β-lactamase inhibitors clavulanate, sulbactam and tazobactam. Metallo-β-lactamases efficiently hydrolyze virtually all broad-spectrum β-lactam antibiotics (but not monobactams), conferring resistance to penicillins, expanded-spectrum cephalosporins and carbapenems.

Metallo-β-lactamases are characteristically found as chromosomally-encoded enzymes in several bacterial species, including *Stenotrophomonas maltophilia*, *Chryseobacterium (Flavobacterium) meningosepticum*, *Aeromonas hydrophila*, *Bacillus cereus* and *B. fragilis* (Livermore and Woodford, 2000; Rasmussen and Bush, 1997). *Stenotrophomonas maltophilia* has emerged as an important nosocomial pathogen (Gales *et al.*, 2001). Identification of a plasmid-like element containing the intrinsic *S. maltophilia* metalloenzyme is disconcerting, since it could be spread to other Gram-negative species (Avison *et al.*, 2001).

Over the past decade, acquired metallo-β-lactamases have been increasingly isolated from a variety of Gram-negative bacteria including *Pseudomonas* spp., *Acinetobacter* spp and *Enterobacteriaceae*. The spread of metallo-β-lactamase-carrying bacteria in hospitals poses a serious threat to effective antimicrobial therapy of nosocomial infections. Four major groups of mobile metallo-β-lactamases have been recognized: the IMP, VIM, SPM and GIM groups. Their genetic determinants are often carried on mobile gene cassettes inserted into plasmid or chromosomal-borne integrons (Nordmann and Poirel, 2002; Toleman *et al.*, 2002; Castanheira *et al.*, 2004). The IMP- and VIM-type enzymes are the prominent representatives, with 17 IMP-type and 11 VIM-type variants reported to date (www.lahey.org/studies/) and their presence is now recognized worldwide.

Table 3: Susceptibility patterns of bacteria possessing metallo-β-lactamases

β-lactamase	Bacteria	No. of isolates (patients)	Country of origin	Imipenem MIC (μg mL <sup>-1</sup> )	ATM MIC (μg mL <sup>-1</sup> )	Concomitant resistance*	References
IMP	<i>P. aeruginosa</i>	15	Japan	2->128	4->128	MEM,CAZ,GM, TOB, AK, CIP	Senda <i>et al.</i> (1996)
IMP	<i>P. aeruginosa</i>	53	Japan	2->128	1->128	CAZ,GM,CIP	Hirakata <i>et al.</i> (1998)
VIM	<i>P. aeruginosa</i>	7	Greece	>128	32-64	CAZ,FEP,CIP,GM,AK,TZB	Tsakris <i>et al.</i> (2000)
VIM-1	<i>P. aeruginosa</i>	8	Italy	>128	4-32	MEM,FEP,TZB,GM,AK,CIP	Cornaglia <i>et al.</i> (2000)
VIM	<i>P. aeruginosa</i>	45	Korea	8->128		CAZ	Lee <i>et al.</i> (2004)
VIM	<i>P. putida</i>	7	Korea	64->128		CAZ	Lee <i>et al.</i> (2004)
IMP	<i>A. baumannii</i>	9	Japan	8-16	4-32	CAZ,CTX,AK,GM	Takahashi <i>et al.</i> (2000)
IMP-4	<i>Acinetobacter</i> spp.	23	Hong Kong	0.25-16	2-64	TZB,CTX	Chu <i>et al.</i> (2001)
IMP	<i>Acinetobacter</i> spp.	17	Korea	8-32		CAZ	Lee <i>et al.</i> (2004)
VIM	<i>Acinetobacter</i> spp.	16	Korea	4-32		CAZ	Lee <i>et al.</i> (2004)
GIM	<i>P. aeruginosa</i>	5	Germany	>8	8-16	TZB,CAZ,CIP,GM,TOB	Castanheira <i>et al.</i> (2004)
IMP-8	<i>K. pneumoniae</i>	17	Taiwan	0.25->256	0.06->256	CAZ,GM,TOB,CIP	Yan <i>et al.</i> (2001)
IMP-8	<i>E. cloacae</i>	20	Taiwan	0.25-8	0.002->256	GM,TOB,CAZ	Arakawa <i>et al.</i> (2000)
IMP	<i>S. marcescens</i>	4	Japan	8->128	2-8	CAZ, CIP	Ito <i>et al.</i> (1995)

\* AK = amikacin; ATM = aztreonam; CAZ = ceftazidime; CIP = ciprofloxacin; CTX = cefotaxime; FEP = cefepime; GM = gentamicin; MEM = meropenem; TOB = tobramycin; TZB = piperacillin-tazobactam

IMP-1 was first detected in 1991 in an isolate of *S. marcescens* from Japan (Osana *et al.*, 1994) and soon after was found in several other Gram-negative species (Ito *et al.*, 1995; Kurokawa, *et al.*, 1999; Takahashi *et al.*, 2000; Hirakata *et al.*, 1998; Senda *et al.*, 1996). In a Japanese survey conducted in 1996-1997, 1.3% of *P. aeruginosa* and 4.4% of *S. marcescens* isolates produced IMP-1. This enzyme was also detected in other Gram-negative bacilli, including *K. pneumoniae*, *Citrobacter freundii*, *Enterobacter* spp., *Proteus vulgaris*, *Providencia rettgeri*, *Pseudomonas putida* and *fluorescens*, *Burkholderia cepacia*, *Alcaligenes xylosoxidans* and *Acinetobacter* spp. (Kurokawa *et al.*, 1999). More recently, a longitudinal sample of Japanese isolates from the SENTRY Antimicrobial Surveillance Program, collected from 1998 to 2002, revealed that metallo-β-lactamase-producing strains of several species have persisted in Japan (Jones *et al.*, 2004). The IMP β-lactamases have spread to other regions in Asia (including Korea, Taiwan and Hong Kong) and have been reported in bacteria from Europe and Canada (Lee *et al.*, 2003; Yan *et al.*, 2001b; Chu *et al.*, 2001; Woodford *et al.*, 1998; Cornaglia *et al.*, 1999; Gibb *et al.*, 2002).

The second major family, VIM-type metallo-β-lactamases, were initially described in isolates from European countries. VIM-1 was identified in a *P. aeruginosa* isolate collected in Verona, Italy in 1996 (Lauretto *et al.*, 1999), VIM-type variants have since been recovered in clinical isolates of *P. aeruginosa*, *Acinetobacter* spp., and enteric Gram-negative bacteria (including *Escherichia coli*, *K. pneumoniae*, *S. marcescens*, *E. cloacae*) from Europe, the Far East and the United States (Tsakris *et al.*, 2000; Yan *et al.*, 2001a; Yun *et al.*, 2002; Toleman *et al.*, 2004).

SPM-1 and GIM-1 appear thus far to be restricted to *P. aeruginosa* isolates in Brazil and Germany, respectively (Toleman *et al.*, 2002; Castanheira *et al.*, 2004).

Initially, only sporadic isolates were found possessing metallo-β-lactamases. However, reports of nosocomial outbreaks soon followed (Senda *et al.*, 1996; Yan *et al.*, 2001b; Gibb *et al.*, 2002; Tsakris *et al.*, 2000; Lagatolla *et al.*, 2004; Lee *et al.*, 2004; Toleman *et al.*, 2005). In some regions, metalloenzyme-producing Gram-negative pathogens have become highly endemic. In one medical center in Italy, a significant increase in the prevalence of imipenem-resistant *P. aeruginosa* was noted; *bla*<sub>VIM</sub> was found in 64 of 89 resistant isolates (Lagatolla *et al.*, 2004). In this outbreak, molecular typing revealed that the *bla*<sub>VIM</sub>-positive isolates generally belonged to two clusters. Isolates of VIM-possessing *P. aeruginosa* were detected from inpatients, residents of long-term care facilities and outpatients (Lagatolla *et al.*, 2004). A recent report from the SENTRY Antimicrobial Surveillance Programme suggests that the emergence of metallo-β-lactamases has become a national problem in Italy (Toleman *et al.*, 2005). The original integron harboring the *bla*<sub>VIM-1</sub> gene cassette, In70, was found in different strains throughout Italy. In addition, other novel integrons were identified and a considerable degree of variability in metallo-β-lactamases and integrons existed between geographically distinct regions.

Another study on the prevalence of metallo-β-lactamase -producing isolates came from 28 KONSAR hospitals in Korea (Lee *et al.*, 2004). In this report, 11.1% of resistant *Pseudomonas* spp. and 15.1% of *Acinetobacter* spp. carried metallo-β-lactamases (Lee *et al.*, 2004). Molecular typing showed that many of the *bla*<sub>VIM</sub>-positive *P. aeruginosa* isolates belonged to one large cluster, suggesting intra- and inter-hospital spread of this strain.

Although considered efficient carbapenemases, a close analysis of susceptibility patterns of various metallo-β-lactamases -producing bacteria reveals an imperfect correlation between the presence of various

enzymes and carbapenem susceptibility. Carbapenem MICs in the susceptible- or intermediate range have been frequently encountered, particularly among *Enterobacteriaceae* (Table 3), suggesting other mechanisms are needed for high-level carbapenem resistance. Variations in the degree of metallo- $\beta$ -lactamase expression, decreased outer membrane permeability (Livermore and Woodford, 2000; Koh *et al.*, 2002; Cornaglia *et al.*, 2000) and/or expression of active efflux systems may also contribute to carbapenem resistance. Isolates with carbapenem MICs below the breakpoint for susceptibility will not be suspected of carrying one of these  $\beta$ -lactamases and therefore go unrecognized. The accurate detection of metallo- $\beta$ -lactamase-producing isolates is important for the timely institution of infection control measures and prevention of further dissemination.

Several phenotypic screening methods have been described for identification of metallo- $\beta$ -lactamases. The inhibition of metallo- $\beta$ -lactamases by chelating agents, such as EDTA and 2-mercaptopyruvic acid (2-MPA), served as the basis for screening methods described by several investigators. Two proposed screening methods involve the double-disk synergy test, using ceftazidime (CAZ) and 2-MPA disks (Arakawa *et al.*, 2000) and the imipenem-EDTA disk diffusion method (Yong *et al.*, 2002). However, metallo- $\beta$ -lactamase-producing bacteria may possess additional antibiotic-hydrolyzing enzymes (Yan *et al.*, 2002), which may decrease the sensitivity of these screening tests. Metallo- $\beta$ -lactamase-possessing Gram-negative bacteria with carbapenem MICs in the susceptible range can also be missed using these methods. Yan *et al.* (2004) developed a modified four-disk diffusion method involving chelating agents, cephalosporins and clavulanic acid. Although higher detection rates were noted for several Gram-negative species, lower specificity was observed for *A. baumannii* and *P. aeruginosa* isolates. A commercially available Etest (AB BIODISK, Solna, Sweden) method has been reported to be sensitive in detection of metallo- $\beta$ -lactamases in *Acinetobacter* spp., *P. aeruginosa*, *Serratia* spp., *S. maltophilia*, and *B. fragilis*. (Walsh *et al.*, 2002). The Etest method however, will likely miss metallo- $\beta$ -lactamase -producing *Enterobacteriaceae* with imipenem MICs below 4  $\mu$ g/ml (Yan *et al.*, 2004).

**Therapeutic options:** Because most of the pathogens carrying carbapenem-hydrolyzing enzymes are frequently resistant to all  $\beta$ -lactams and other classes of antimicrobials (aminoglycosides, fluoroquinolones), therapy of serious infections can be exceedingly difficult. For *Acinetobacter* spp., sulbactam frequently demonstrates in vitro activity (Go *et al.*, 1994; Urban *et al.*,

1993; Appleman *et al.*, 2000) and was effective in an animal model of pneumonia (Montero *et al.*, 2002; Wolff *et al.*, 1999). Successful clinical outcomes have also been reported with sulbactam therapy (Urban *et al.*, 1993; Wood *et al.*, 2002; Jimenez-Mejias *et al.*, 1997). However, sulbactam resistance hampers in vivo effectiveness (Montaro *et al.*, 2002; Wolf *et al.*, 1999) and sulbactam-resistant isolates have been frequently encountered in some reports (Wood and Reboli, 1993; Corbella *et al.*, 2000; Landman *et al.*, 2002). Tigecycline has also demonstrated in vitro effectiveness against carbapenem-resistant *A. baumannii* (Pachon-Ibanez *et al.*, 2004), however clinical experience with this antibiotic is unknown.

The emergence of multidrug resistant *A. baumannii* and *P. aeruginosa* has led to a renewed interest in polymyxin E (colistin) and polymyxin B. Most of these isolates remain susceptible to the polymyxins, which act by displacing cations from the outer bacterial cell membrane. Successful outcomes following polymyxin therapy have been noted in patients with serious infections, including bacteremias, urinary tract infections and neurosurgical-related meningitis (Table 4; Wood and Reboli, 1993; Levin *et al.*, 1999; Basen *et al.*, 2000; Femandex-Viladrich *et al.*, 1999). However, poorer clinical and microbiological response rates (typically ~25-60%) have been noted for therapy of nosocomial pneumonia due to *A. baumannii* and *P. aeruginosa* (Levin *et al.*, 1999; Linden *et al.*, 2003; Ouderkirk *et al.*, 2003). A poor response rate to parenteral colistin therapy has also been documented in an animal model of *A. baumannii* pneumonia (Montaro *et al.*, 2002). Nephrotoxicity rates of 10-37% have been observed with parenteral polymyxin therapy (Levin *et al.*, 1999; Ouderkirk *et al.*, 2003; Sobieszcyk *et al.*, 2004). However, in one report involving patients with ventilator-associated pneumonia due to *A. baumannii*, the outcomes and toxicities of colistin therapy were similar to imipenem therapy of the carbapenem-susceptible isolates (Garnacho-Montero *et al.*, 2003).

The poor response rates involving parenteral polymyxin therapy have prompted searches for antibiotic combinations to improve outcomes (Table 5). Several novel combinations have demonstrated improved activity against multidrug resistant *A. baumannii*. Enhanced in vitro activity has been observed with combinations involving sulbactam and azithromycin (Appleman *et al.*, 2000), colistin and rifampin (Hogg *et al.*, 1998), polymyxin with azithromycin (Manikal *et al.*, 2000) and polymyxin B with rifampin and/or imipenem (Yoon *et al.*, 2004). In an experimental model of pneumonia involving a highly imipenem resistant strain of *A. baumannii* carrying OXA-

Table 4: Summary of clinical studies involving colistin therapy for multidrug resistant pathogens

Bacteria	No. of cases	Site of infections	Therapy	Favorable clinical outcome (%)	Microbiological cure (%)	Renal toxicity (%)	Comments	References
<i>A. baumannii</i>	21	Respiratory	IV colistin alone	57	66	24	Outcome similar to imipenem group	Garnacho-Montero <i>et al.</i> (2003)
<i>A. baumannii</i> and <i>P. aeruginosa</i>	71	Respiratory	Inhaled colistin		92	0		Berlana <i>et al.</i> (2005)
<i>A. baumannii</i> and <i>P. aeruginosa</i>	20	Respiratory	IV colistin	25		37		Levin <i>et al.</i> (1999)
	12	Urine	IV colistin	83				
	9	Bacteremia	IV colistin	78				
<i>A. baumannii</i> , <i>P. aeruginosa</i> , <i>A. xylosoxidans</i>	29	Respiratory	IV and/or inhaled polymyxin B	76	41	10	65% also with imipenem, 38% with aminoglycoside	Sobieszczyk <i>et al.</i> (2004)
<i>P. aeruginosa</i>	18	Respiratory	IV colistin	56	33			
	6	Abdominal		83	67			Linden <i>et al.</i> (2003)
<i>A. baumannii</i> and <i>P. aeruginosa</i>	60	Mixed	IV Polymyxin B	88	14			Ouderkirk <i>et al.</i> (2003)

Table 5: In vitro studies involving polymyxins against carbapenem-resistant bacteria

Bacteria	No. of isolates tested	Combinations with enhanced activity (% of isolates)	Comments	References
<i>A. baumannii</i>	13	Colistin+rifampin (85%)		Hogg <i>et al.</i> (1998)
<i>A. baumannii</i>	8	Polymyxin B + imipenem and/or rifampin (87-100%)	Triple combination bactericidal 8/8	Yoon <i>et al.</i> (2004)
<i>P. aeruginosa</i>	13	Polymyxin B + azithromycin		Bratu <i>et al.</i> (2005c)
<i>P. aeruginosa</i>	10	Polymyxin B + imipenem and/or rifampin (80-100%)	Polymyxin B resistant isolates	Landman <i>et al.</i> (2005)
<i>K. pneumoniae</i>	16	Polymyxin B + rifampin	KPC-2	Bratu <i>et al.</i> (2005e)

24, improved outcome was observed with various combinations involving rifampin, sulbactam, tobramycin and imipenem (Montero *et al.*, 2004). Similarly, for *P. aeruginosa*, increased in vitro killing of highly-resistant strains has been noted with polymyxin B and azithromycin, imipenem and/or rifampin (Bratu *et al.*, 2005c; Landman *et al.*, 2005). Whether any of these combinations results in superior clinical or microbiological outcome remains to be determined. Aerosolized colistin or polymyxin B has been used to treat hospital-acquired pneumonia due to these pathogens, with high rates of microbiological clearance and apparently little risk of nephrotoxicity (Sobieszczyk *et al.*, 2004; Hamer, 2000; Berlana *et al.*, 2005). Aerosolized colistin therapy has been suggested also as an infection control measure to eradicate respiratory colonization (Urban *et al.*, 2003). Fortunately, polymyxin resistance has been unusual to date, occurring in ~0-5% of isolates (Appleman *et al.*, 2000; Linden *et al.*, 2003; Ouderkirk *et al.*, 2003; Manikal *et al.*, 2000; Bratu *et al.*, 2005c; Landman *et al.*, 2005; Hamer, 2000; Berlana *et al.*, 2005).

Therapy of infections due to carbapenem-resistant *K. pneumoniae* is equally difficult. For isolates possessing KPC  $\beta$ -lactamases, resistance to all  $\beta$ -lactams, fluoroquinolones and most aminoglycosides is common (Bradford *et al.*, 2004; Bratu *et al.*, 2005b; Woodford *et al.*, 2004). Combining imipenem with the  $\beta$ -lactamase inhibitor clavulanic acid only lowers the imipenem MIC by approximately 2-4 dilutions and is not likely to be an

effective regimen (Woodford *et al.*, 2004; Bratu *et al.*, 2005e). Although many of these isolates appear susceptible to tetracycline, the MICs hover around the breakpoint for this antibiotic and time kill studies do not suggest this will be an effective therapy (Woodford *et al.*, 2004; Urban *et al.*, 2003). KPC-possessing *K. pneumoniae* are susceptible to the glycolcycline antibiotic tigecycline (Bratu *et al.*, 2005b), but clinical experience is lacking. Approximately 60% of isolates retain susceptibility to gentamicin and 90% to polymyxin B (Bratu *et al.*, 2005d). Polymyxin B possesses concentration-dependent killing and the combination of polymyxin B and rifampin has demonstrated synergy in time kill studies (Bratu *et al.*, 2005e). Again, the clinical utility of these regimens is unknown.

Many of the outbreaks involving carbapenemase-carrying *A. baumannii*, *P. aeruginosa*, and *K. pneumoniae* tend to involve only a small number of strains. Given the toxicity and poor response rates to polymyxins for many of these infections, preventing transmission of these pathogens is crucial. Compliance to rigorous infection control strategies will be essential in reducing the spread of these nosocomial pathogens.

**ACKNOWLEDGMENTS**

Dr. Quale has received research grants from Merck and Co., Inc.

REFERENCES

- Afzal-Shah, M., N. Woodford and D.M Livermore, 2001. Characterization of OXA-25, OXA-26 and OXA-27, molecular class D  $\beta$ -lactamases associates with carbapenem-resistance in clinical isolates of *Acinetobacter baumannii*. Antimicrob. Agents Chemother., 45: 583-588.
- Afzal-Shah, M., H.E. Villar and D.M. Livermore, 1999. Biochemical characteristics of a carbapenemase from *Acinetobacter baumannii* isolates collected in Buenos Aires, Argentina. J. Antimicrob. Chemother., 43: 127-131.
- Appleman, M.D., H. Belzberg, D.M. Citron, P.N.R. Heseltine, A.E. Yellin, J. Murray and T.V. Berne, 2000. In vitro activities of nontraditional antimicrobials against multiresistant *Acinetobacter baumannii* strains isolates during an intensive care unit outbreak. Antimicrob. Agents Chemother., 44: 1035-1040.
- Arakawa, Y., N. Shibata, K. Shibayama, H. Kurokawa, T. Yagi, H. Fujiwara and M. Goto, 2000. Convenient test for screening metallo- $\beta$ -lactamase-producing gram-negative bacteria by using thio compounds. J. Clin Microbiol., 38: 40-43.
- Avison, M.B., C.S. Higgins, C.J. von Heldreich, P.M. Bennett and T.R. Walsh, 2001. Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of *Stenotrophomonas maltophilia*. Antimicrob. Agents Chemother., 45: 413-4195.
- Basen, W., P. Desmery, S. Ilutovich and A. Di Martino, 2000. Intrathecal use of colistin. J. Clin. Microbiol., 38: 3523.
- Berlana D., J.M. Llop, M.B. Badia and R. Jodar, 2005. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am. J. Health-Syst. Pharm., 62: 39-47.
- Bonnet, R., H. Marchandin, C. Chanal, D. Sirot, R. Labia, C. De Chanips, E. Jumas-Bilak and J. Sirot, 2002. Chromosome-encoded class D beta-lactamase OXA-23 in *Proteus mirabilis*. Antimicrob. Agents Chemother., 46: 2004-2006.
- Bou, G., G. Cervero, M.A. Dominguez, C. Quereda and J. Martinez-Beltran, 2000a. Characterization of a nosocomial outbreak caused by a multiresistant *Acinetobacter baumannii* strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in *A. baumannii* is not due solely to the presence of  $\beta$ -lactamase. J. Clin. Microbiol., 38: 3299-3305.
- Bou, G., A. Oliver and J. Martinez-Beltran, 2000b. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. Antimicrob. Agents Chemother., 44: 1556-1561.
- Bradford, P.A., S. Bratu, C. Urban, M. Visalli, N. Mariano, D. Landman, J.J. Rahal, S. Brooks, S. Cebular and J. Quale, 2004. Emergence of carbapenem-resistant *Klebsiella* species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30  $\beta$ -lactamases in New York City. Clin. Infect. Dis., 39: 55-60.
- Bradford, P.A., C. Urban, N. Mariano, S.J. Projan, J.J. Rahal and K. Bush, 1997. Imipenem resistance in *Klebsiella pneumoniae* is associated with the combination of ACT-1, a plasmid-mediated AmpC  $\beta$ -lactamase and the loss of an outer membrane protein. Antimicrob. Agents Chemother., 41: 563-569.
- Bratu, S., D. Landman M. Alam, E. Tolentino and J. Quale, 2005a. Detection of KPC carbapenem-hydrolyzing enzymes in *Enterobacter* spp. from Brooklyn, NY. Antimicrob. Agents Chemother., 49: 776-778.
- Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam and J. Quale. 2005b. Rapid spread of carbapenem-resistant *Klebsiella pneumoniae* in New York City: A new threat to our antibiotic armamentarium. Arch. Intl. Med., 165: 1430-1435.
- Bratu, S., J. Quale, S. Cebular, R. Heddurshetti and D. Landman, 2005c. Multidrug-resistant *Pseudomonas aeruginosa* in Brooklyn, NY: Molecular epidemiology and in vitro activity of polymyxin. Eur. J. Clin. Microbiol. Infect. Dis., 24: 196-201.
- Bratu, S., M. Mooty, S. Nichani, D. Landman C. Gullans, B. Pettinato, U. Karumudi, P. Tolaney and J. Quale, 2005d. Emergence of KPC-possessing *Klebsiella pneumoniae* in Brooklyn, NY: Epidemiology and recommendations for detection. Antimicrob. Agents Chemother., 49: 3018-3020.
- Bratu, S., P. Tolaney, U. Karamudi, J. Quale, M. Mooty, S. Nichani and D. Landman, 2005e. Carbapenemase-producing *Klebsiella pneumoniae* in Brooklyn, NY: Molecular epidemiology and in-vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother., 56: 128-132.
- Brown, S., C. Bantar, H.-K. Young and S.G.B. Amyes, 1998. Limitation of *Acinetobacter baumannii* treatment by plasmid-mediated carbapenemase ARI-2. Lancet, 351: 186-187.



- Cao, V.T.B., G. Arlet, B.M. Ericsson, A. Tammelin, P. Courvalin and T. Lambert, 2000. Emergence of imipenem resistance in *Klebsiella pneumoniae* owing to combination of plasmid-mediated CMY-4 and permeability alteration. J. Antimicrob. Chemother., 46: 895-900.
- Castanheira, M., M.A. Toleman, R.N. Jones, F.J. Schmidt and T.R. Walsh, 2004. Molecular characterization of a  $\beta$ -lactamase gene, *bla*<sub>GIM-1</sub>, encoding a new subclass of metallo- $\beta$ -lactamase. Antimicrob. Agents Chemother., 48: 4654-4661.
- Chow, J.W. and D.M. Shlaes, 1991. Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in *Enterobacter aerogenes*. J. Antimicrob. Chemother., 28: 499-504.
- Chu, Y.W., M. Afzal-Shah, E.T.S. Houang, M-F.I. Palepou, D.J. Lyon, N. Woodford and D. Livermore, 2001. IMP-4, a novel metallo- $\beta$ -lactamase from nosocomial *Acinetobacter spp.* collected in Hong Kong between 1994 and 1998. Antimicrob. Agents Chemother., 45: 710-714.
- Corbella, X., A. Montero, M. Pujol, M.A. Dominguez, J. Ayats, M.J. Argerich, F. Garrigosa, J. Ariza and F. Gudiol, 2000. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant *Acinetobacter baumannii*. J. Clin. Microbiol., 38: 4086-4095.
- Cornaglia, G., A. Mazzariol, L. Lauretti, G.M. Rossolini and R. Fontana, 2000. Hospital outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing VIM-1, a novel transferable metallo- $\beta$ -lactamase. Clin. Infect. Dis., 31: 1119-1125.
- Cornaglia, G., M.L. Riccio, A. Mazariol, L. Lauretti, R. Fontana and G.M. Rossolini, 1999. Appearance of IMP-1 metallo- $\beta$ -lactamase in Europe. Lancet, 353: 899-900.
- Dalla-Costa, L.M., J.M. Coelho, H.A.P.H.M. Souza, M.E.S. Castro, C.J.N. Stier, K.L. Bragagnolo, A. Rea-Neto, S.R. Penteado-Filho, D.M. Livermore and Neil Woodford, 2003. Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the OXA-23 enzyme in Curitiba, Brazil. J. Clin. Microbiol., 41: 3403-3406.
- Donald, H.M., W. Scaife, S.G.B. Amyes and H-K. Young, 2000. Sequence analysis of ARI-1, a novel OXA  $\beta$ -lactamase, responsible for imipenem resistance in *Acinetobacter baumannii* 6B92. Antimicrob. Agents Chemother., 44: 196-199.
- Fernandez-Viladrich, P., X. Corbella, L. Corral, F. Tubau and A. Mateu, 1999. Successful treatment of ventriculitis due to carbapenem-resistant *Acinetobacter baumannii* with intraventricular colistin sulfomethate sodium. Clin. Infect. Dis., 28: 916-917.
- Gales, A.C., R.N. Jones, K.R. Forward, J. Linares, H.S. Sader and J. Verhoef, 2001. Emerging importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas maltophilia* as pathogens in seriously ill patients: Geographic patterns, epidemiologic features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis., 32: 104-113.
- Garnacho-Montero, J., C. Ortiz-Leyba, F.J. Jimenez-Jimenez, A.E. Barrero-Almodovar, J.L. Garcia-Garmendia, M. Bernabeu-Wittell, S.L. Gallego-Lara and J. Madrazo-Osuna, 2003. Treatment of multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin. Infect. Dis., 36: 1111-1118.
- Gibb, A.P., C. Tribuddharat, R.A. Moore, T.J. Louie, W. Krulicki, D.M. Livermore, M-F.I. Palepou and N. Woodford, 2002. Nosocomial outbreak of carbapenem-resistant *Pseudomonas aeruginosa* with a new *bla*<sub>IMP</sub> allele, *bla*<sub>IMP-4</sub>. Antimicrob. Agents Chemother., 46: 255-258.
- Go, E.S., C. Urban, J. Burns, B. Kreiswirth, W. Eisner, N. Mariano, K. Mosinka-Snipas and J.J. Rahal, 1994. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet, 344: 1329-1332.
- Hamer, D.H., 2000. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant *Pseudomonas aeruginosa* with aerosolized colistin. Am. J. Respir. Crit. Care Med., 162: 328-330.
- Heritier, C., A. Dubouix, L. Poirel, N. Marty and P. Nordmann, 2005. A nosocomial outbreak of *Acinetobacter baumannii* isolates expressing the carbapenem-hydrolyzing oxacillinase OXA-58. J. Antimicrob. Chemother., 55: 115-118.
- Heritier, C., L. Poirel, D. Aubert and P. Nordmann, 2003. Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of *Acinetobacter baumannii*. Antimicrob. Agents Chemother., 47: 268-273.
- Hirakata, Y., K. Izumikawa, T. Yamaguchi, H. Takemura, H. Tanaka, R. Yoshida, J. Matsuda, M. Nakano, K. Tomono, S. Maesaki, M. Kaku, Y. Yamada, S. Kamihira and S. Kohno, 1998. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant Gram-negative rods carrying the metallo- $\beta$ -lactamase gene *bla*<sub>IMP</sub>. Antimicrob. Agents Chemother., 42: 2006-2011.
- Hogg, G.M., J.G. Barr and C.H. Webb, 1998. *In vitro* activity of the combination of colistin and rifampicin against multidrug-resistant strains of *Acinetobacter baumannii*. J. Antimicrob. Chemother., 41: 494-495.

- Hong, T., E.S. Moland, B. Abdalhamid, N.D. Hanson, J. Wang, C. Sloan, D. Fabian, A. Farajallah, J. Levine and K. S. Thomson, 2005. *Escherichia coli*: Development of carbapenem resistance during therapy. Clin. Infect. Dis., 40: 84-86.
- Hossain, A., M.J. Ferraro, R.M. Pino, R.B. Dew, III, E.S. Moland, T.J. Lockhart, K.S. Thomson, R.V. Goering and N.D. Hanson, 2004. Plasmid-mediated carbapenem hydrolyzing enzyme KPC-2 in *Enterobacter* sp. Antimicrob. Agents Chemother., 48: 4438-4440.
- Ito, H., Y. Arakawa, S. Ohsuka, R. Wacharotayankun, N. Kato and M. Ohta, 1995. Plasmid-mediated dissemination of the metallo- $\beta$ -lactamase gene *bla*<sub>IMP</sub> among clinically isolated strains of *Serratia marcescens*. Antimicrob. Agents Chemother., 39: 824-829.
- Jimenez-Mejias, M.E., J. Pachon, B. Becerril, J. Palomino-Nicas, A. Rodriguez-Cobacho and M. Revuelta, 1997. Treatment of multidrug-resistant *Acinetobacter baumannii* meningitis with ampicillin/sulbactam. Clin. Infect. Dis., 24: 932-935.
- Jones, R.N., L.M. Desphande, J.M. Bell, J.D. Turnidge, S. Kohno, Y. Hirakata, Y. Ono, Y. Miyazawa, S. Kawakama, M. Inoue, Y. Hirata, M.A. Toleman, 2004. Evaluation of the contemporary occurrence rates of metallo- $\beta$ -lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Diagn. Microbiol. Infect. Dis., 49: 289-294.
- Koh, T.H., L.H. Sng, G.S. Babini, N. Woodford, D.M. Livermore and L.M.C. Hall, 2002. Carbapenem-resistant *Klebsiella pneumoniae* in Singapore producing IMP-1  $\beta$ -lactamase and lacking an outer membrane protein. Antimicrob. Agents Chemother., 45: 1939-1940.
- Kurokawa, H., T. Yagi, N. Shibata, K. Shibayama and Y. Arakawa, 1999. Worldwide proliferation of carbapenem-resistant gram-negative bacteria. Lancet, 354: 955.
- Lagatolla, C., E.A., C. Tonin, L. Monti-Bragadin, Dolzani, F. Gombac, C. Bearzi, E. Edalucci, F. Gionechetti and G.M. Rossolini, 2004. Endemic carbapenem-resistant *Pseudomonas aeruginosa* with acquired metallo- $\beta$ -lactamase determinants in European Hospitals. Emerg. Infect. Dis., 10: 535-538.
- Landman, D., S. Bratu, M. Alam and J. Quale, 2005. Citywide emergence of *Pseudomonas aeruginosa* strains with reduced susceptibility to polymyxin B.J. Antimicrob. Chemother., 55: 954-957.
- Landman, D., J.M. Quale, D. Mayorga, A. Adedeji, K. Vangala, J. Ravishankar, C. Flore and S. Brooks, 2002. Citywide clonal outbreak of multiresistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in Brooklyn, NY. The preantibiotic era has returned. Arch. Intern. Med., 162: 1515-1520.
- Lauretti, L., M.L. Riccio, A. Mazariol, G. Comaglia, G. Amicosante, R. Fontana and G.M. Rossolini, 1999. Cloning and characterization of *bla*<sub>VIM6</sub>, a new integron-borne metallo- $\beta$ -lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. Antimicrob. Agents Chemother., 43: 1584-1590.
- Lee, K., G.Y. Ha, B.M. Shin, J.J. Kim, J.O. Kang, S.J. Jang, D.Y. Yong, Y. Chong and the Korean Nationwide Surveillance of Antimicrobial Resistance (KONSAR) group, 2004. Metallo- $\beta$ -lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: Continued prevalence of VIM-producing *Pseudomonas spp.* and increase in IMP-producing *Acinetobacter spp.* Diagn. Microbiol. Infect. Dis., 50: 51-58.
- Lee, K., W.G. Lee, Y. Uh, G.Y. Ha, J. Cho and Y. Chong, 2003. Korean Nationwide Surveillance of Antimicrobial Resistance Group. VIM- and IMP- type metallo-beta-lactamase-producing *Pseudomonas spp.* and *Acinetobacter spp.* in Korean hospitals. Emerg. Infect. Dis., 9: 868-871.
- Levin, A.S., A.A. Barone, J. Penco, M.V. Santos, I.S. Marinho, E.A.G. Arruda, E.I. Manrique and S.F Costa, 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Clin. Infect. Dis., 28: 1008-1011.
- Linden, P.K., S. Kusne, K. Coley, P. Fontes, D.J. Kramer and D. Paterson, 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant *Pseudomonas aeruginosa*. Clin. Infect. Dis., 37: 154-160.
- Livermore, D.L., 1992. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother., 36: 2046-2048.
- Livermore, D. and N. Woodford, 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol., 3: 489-495.
- Lopez-Otsoa, F., L. Gallego and K.J. Towner *et al.* 2002. Endemic carbapenem resistance associated with OXA-40 carbapenemase among *Acinetobacter baumannii* isolates from a hospital in northern Spain. J. Clin. Microbiol., 40: 4741-4743.

- Manikal, V.M., D. Landman, G. Saurina, E. Oydna, H. Lal and J. Quale, 2000. Endemic carbapenem-resistant *Acinetobacter* species in Brooklyn, NY: Citywide prevalence, interinstitutional spread and relation to antibiotic usage. Clin. Infect. Dis., 31: 101-106.
- Martinez-Martinez, L., A. Pascual, S. Hernandez-Alles, D. Alvarez-Diaz, A.I. Suarez, J. Tran, V.J. Benedi and G.A. Jacoby, 1999. Roles of  $\beta$ -lactamases and porins in activities of carbapenems and cephalosporins against *Klebsiella pneumoniae*. Antimicrob. Agents Chemother., 43: 1669-1673.
- Miriagou, V., L.S. Tzouveleki, S. Rossiter, E. Tzelepi, F.J. Angulo, J.M. Whichard, 2003. Imipenem resistance in a *Salmonella* clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother., 47: 1297-1300.
- Moland, E.S., N.D. Hanson, V.L. Herrera, J.A. Black, T.J. Lockhart, A. Hossain, J.J. Johnson, R.V. Goering and K.S. Thomson, 2003. Plasmid-mediated, carbapenem-hydrolysing  $\beta$ -lactamase, KPC-2, in *Klebsiella pneumoniae* isolates. J. Antimicrob. Chemother., 51: 711-714.
- Montero, A., J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy and F. Gudiol, 2002. Efficacy of colistin versus  $\beta$ -lactams, aminoglycosides and rifampin as monotherapy in a mouse model of pneumonia caused by multidrug-resistant *Acinetobacter baumannii*. Antimicrob. Agents Chemother., 46: 1946-1952.
- Montero, A., J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Borraz and F. Gudiol, 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant *Acinetobacter baumannii* in a mouse pneumonia model. J. Antimicrob. Chemother., 54: 1085-1091.
- Naas, T. and P. Nordmann, 1994. Analysis of a carbapenem-hydrolyzing class A  $\beta$ -lactamase from *Enterobacter cloacae* and of its LysR-type regulatory protein. Proc. Natl. Acad. Sci., 91: 7693-7697.
- Naas, T., L. Vandael, W. Sougakoff, D.M. Livermore and P. Nordmann, 1994. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A  $\beta$ -lactamase, Sme-1, from *Serratia marcescens* S6. Antimicrob. Agents Chemother., 38: 1262-1270.
- Nordmann, P., S. Mariotte, T. Naas, R. Labia and M.H. Nicolas, 1993. Biochemical properties of a carbapenem-hydrolyzing  $\beta$ -lactamase from *Enterobacter cloacae* and cloning of the gene into *Escherichia coli*. Antimicrob. Agents Chemother., 37: 939-946.
- Nordmann, P. and L. Poirel, 2002. Emerging carbapenemases in gram-negative aerobes. Clin. Microbiol. Infect., 8: 321-331.
- Osana, E., Y. Arakawa, R. Wacharotayankun, M. Ohta, T. Horii, H. Ito, F. Yoshimura and N. Kato, 1994. Molecular characterization of an enterobacterial metallo-beta-lactamase found in a clinical isolate of *Serratia marcescens* that shows imipenem resistance. Antimicrob. Agents Chemother., 38: 71-78.
- Ouderkirk, J.P., J.A. Nord, G.S. Turett and J.W. Kislak, 2003. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multidrug-resistant Gram-negative bacteria. Antimicrob. Agents Chemother., 47: 2659-2662.
- Pachon-Ibanez, M.E., M.E. Jimenez-Mejias, C. Pichardo, A.C. Llanos and J. Pachon, 2004. Activity of tigecycline (GAR-936) against *Acinetobacter baumannii* strains, including those resistant to imipenem. Antimicrob. Agents Chemother., 48: 4479-4481.
- Pai, H., J-W. Kim, J. Kim, J.H. Lee, K.W. Choe and N. Gotoh, 2001. Carbapenem resistance mechanisms in *Pseudomonas aeruginosa* clinical isolates. Antimicrob. Agents Chemother., 45: 480-484.
- Paton, R., R.S. Mikes, J. Hood and S.G.B. Amyes, 1993. ARI-1:  $\beta$ -lactamase-mediated imipenem resistance in *Acinetobacter baumannii*. Int. J. Antimicrob. Agents, 2: 81-88.
- Poirel, L., G.F. Weldhagen, T. Naas, C. De Champs, M.G. Dove and P. Nordmann, 2001. GES-2, a class A  $\beta$ -lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. Antimicrob. Agents Chemother., 45: 2598-2603.
- Poirel, L., C. Heritier, V. Tolun and P. Nordmann, 2004. Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. Antimicrob. Agents Chemother., 48: 15-22.
- Poirel, L., S. Marque, C. Heritier, C. Segonds, G. Chabanon and P. Nordmann, 2005. OXA-58, a novel class D  $\beta$ -lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. Antimicrob. Agents Chemother., 49: 202-208.
- Pottumarthy, S., E. Smith Moland, S. Juretschko, S.R. Swanzy, K.S. Thomson and T.R. Fritsche, 2003. NmcA carbapenem-hydrolyzing enzyme in *Enterobacter cloacae* in North America. Emerg. Infect. Dis., 9: 999-1002.
- Quale, J., S. Bratu, D. Landman and R. Heddurshetti, 2003. Molecular epidemiology and mechanisms of carbapenem resistance in *Acinetobacter baumannii* endemic in New York City. Clin. Infect. Dis., 37: 214-220.

- Queenan, A.M., C. Torres-Viera, H.S. Gold, Y. Carmeli, G.M. Eliopoulos, R.C. Moellering, Jr., J.P. Quinn, J. Hindler, A.A. Medeiros and K. Bush, 2000. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse *Serratia marcescens* strains. *Antimicrob. Agents Chemother.*, 44: 3035-3039.
- Rasmussen, B.A. and K. Bush, 1997. Carbapenem-hydrolyzing beta-lactamases. *Antimicrob. Agents Chemother.*, 41: 223-232.
- Rasmussen, B.A., K. Bush, D. Keeney, Y. Yang, R. Hare, C. O'Gara and A.A. Medeiros, 1996. Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from *Enterobacter cloacae*. *Antimicrob. Agents Chemother.*, 40: 2080-2086.
- Senda, K., Y. Arakawa, K. Nakashima, H. Ito, S. Itchihama, K. Shimokata, N. Kato and M. Ohta, 1996. Multifocal outbreaks of metallo- $\beta$ -lactamase-producing *Pseudomonas aeruginosa* resistant to broad-spectrum  $\beta$ -lactams, including carbapenems. *Antimicrob. Agents Chemother.*, 40: 349-353.
- Sobieszczyk, M.E., E.Y. Furuya, C.M. Hay, P. Pancholi, P. Della-Latta, S.M. Hammer and C.J. Kubin, 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. *J. Antimicrob. Chemother.*, 54: 566-569.
- Takahashi, A., S. Yomoda, I. Kobayashi, T. Okubo, M. Tsunoda and S. Iyobe, 2000. Detection of carbapenemase-producing *Acinetobacter baumannii* in a hospital. *J. Clin. Microbiol.*, 38: 526-529.
- Toleman, M.A., A.M. Simm, T.A. Murphy, A.C. Gales, D. J. Biedenbach, R. N. Jones and T.R. Walsh, 2002. Molecular characterization of SPM-1, a novel metallo- $\beta$ -lactamase isolated in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. *J. Antimicrob. Chemother.*, 50: 673-679.
- Toleman, M.A., K. Rolston, R.N. Jones and T.R. Walsh, 2004. *Bla<sub>VIM-7</sub>*, an evolutionary distinct metallo- $\beta$ -lactamase gene in a *Pseudomonas aeruginosa* isolate from the United States. *Antimicrob. Agents Chemother.*, 48: 329-332.
- Toleman, M.A., D. Biedenbach, D.M.C. Bennett, R.N. Jones and T.R. Walsh, 2005. Italian metallo- $\beta$ -lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. *J. Antimicrob. Chemother.*, 55: 61-70.
- Tsakris, A., S. Pournaras, N. Woodford, M-F.I. Palepou, G.S. Babini, J. Douboyas and D.M. Livermore, 2000. Outbreak of infections caused by *Pseudomonas aeruginosa* producing VIM-1 carbapenemase in Greece. *Antimicrob. Agents Chemother.*, 38: 1290-1292.
- Urban, C., E. Go, N. Mariano, B.J. Berger, I. Avraham, D. Rubin and J.J. Rahal, 1993. Effect of sulbactam on infections caused by imipenem-resistant *Acinetobacter calcoaceticus* biotype *anitratus*. *J. Infect. Dis.*, 167: 448-451.
- Urban, C., S. Segal-Maurer and J.J. Rahal, 2003. Considerations in control and treatment of nosocomial infections due to multidrug-resistant *Acinetobacter baumannii*. *Clin. Infect. Dis.*, 36: 1268-1274.
- Walsh, T.R., A. Bolmstrom and A. Gales, 2002. Evaluation of a new Etest for detecting metallo- $\beta$ -lactamases in routine clinical testing. *J. Clin. Microbiol.*, 40: 2755-2759.
- Wolff, M., M-L. Joly-Guillou, R. Farinotti and C. Carbon, 1999. In vivo efficacies of combinations of  $\beta$ -lactams,  $\beta$ -lactamase inhibitors and rifampin against *Acinetobacter baumannii* in a mouse pneumonia model. *Antimicrob. Agents Chemother.*, 43: 1406-1411.
- Wood, G.C., S.D. Hanes, M.A. Croce, T.C. Fabian and B.A. Boucher, 2002. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of *Acinetobacter* ventilator-associated pneumonia. *Clin. Infect. Dis.*, 34: 1425-1430.
- Wood, C.A. and A.C. Reboli, 1993. Infections caused by imipenem-resistant *Acinetobacter calcoaceticus* biotype *anitratus*. *J. Infect. Dis.*, 168: 1602-1603
- Woodford, N, M-F.I. Palepou, G.S. Babini, J. Bates and D.M. Livermore, 1998. Carbapenemase-producing *Pseudomonas aeruginosa* in the U.K. *Lancet*, 352: 546-547.
- Woodford, N., P.M. Tierno Jr, K. Young, L. Tysall, M-F. I. Palepou, E. Ward, R.E. Painter, D.F. Suber, D. Shungu, L.L. Silver, K. Inglima, J. Kornblum and D.M. Livermore, 2004. Outbreak of *Klebsiella pneumoniae* producing a new carbapenem-hydrolyzing class A  $\beta$ -lactamase, KPC-3, in a New York Medical Center. *Antimicrob. Agents Chemother.*, 48: 4793-4799.
- Yan, J.J., P.R. Hsueh, W.C. Ko, K.T. Luh, S.H. Tsai, H.M. Wu, J.J. Wu, 2001a. Metallo- $\beta$ -lactamases in clinical *Pseudomonas* isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. *Antimicrob. Agents Chemother.*, 45: 2224-2228.
- Yan, J.J., W.C. Ko, S.H. Tsai, H.M. Wu and J.J. Wu, 2001b. Outbreak of infection with multidrug-resistant *Klebsiella pneumoniae* carrying *bla<sub>IMP-8</sub>* in a university medical center in Taiwan. *J. Clin. Microbiol.*, 39: 4433-4439.
- Yan, J.J., W.C. Ko, C.L. Chuang and J.J. Wu, 2002. Metallo- $\beta$ -lactamase-producing *Enterobacteriaceae* isolates in a university hospital in Taiwan: prevalence of IMP-8 in *Enterobacter cloacae* and first identification of VIM-2 in *Citrobacter freundii*. *J. Antimicrob. Chemother.*, 50: 503-511.

- Yan, J.J., J.J. Wu, S.H. Tsai and C.L. Chuang, 2004. Comparison of the double-disk, combined disk and E-test methods for detecting metallo- $\beta$ -lactamases in Gram-negative bacilli. *Diagn. Microbiol. Infect. Dis.*, 49: 5-11.
- Yigit, H., A.M. Queenan, G.J. Anderson, A. Domenech-Sanchez, J.W. Biddle, C.D. Steward, S. Alberti, K. Bush and F.C. Tenover, 2001. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.*, 45: 1151-1161.
- Yigit, H., G.J. Anderson, J.W. Biddle, C.D. Steward, J.K. Rasheed, L.L. Valera, J.E. McGowen, Jr. and F.C. Tenover, 2002. Carbapenem resistance in a clinical isolate of *Enterobacter aerogenes* is associated with decreased expression of OmpF and OmpC porin analogs. *Antimicrob. Agents Chemother.*, 46: 3817-3822.
- Yigit, H., A.M. Queenan, J.K. Rasheed, J.W. Biddle, A. Domenech-Sanchez, S. Alberti, K. Bush and F.C. Tenover, 2003. Carbapenem-resistant strain of *Klebsiella oxytoca* harboring carbapenem-hydrolyzing  $\beta$ -lactamase KPC-2. *Antimicrob. Agents Chemother.*, 47: 3881-3889.
- Yong, D., K. Lee, J.H. Yum, H.B. Shin, G.M. Rossolini and Y. Chong, 2002. Imipenem-EDTA disk method for differentiation of metallo- $\beta$ -lactamase-producing clinical isolates of *Pseudomonas spp.* and *Acinetobacter spp.* *J. Clin. Microbiol.*, 40: 3798-3801.
- Yoon, J., C. Urban, C. Terzian, N. Mariano and J.J. Rahal, 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem and rifampin against multidrug-resistant *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.*, 2004: 48: 753-757.
- Yum, J.H., D. Yong, K. Lee, H.S. Kim and Y. Chong, 2002. A new integron carrying VIM-2 metallo- $\beta$ -lactamase gene cassette in a *Serratia marcescens* isolate. *Diagn. Microbiol. Infect. Dis.*, 42: 217-219.